The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient ...

Three industry veterans bring decades of strategic consultancy experience across the US, EU, and Asia Pacific to better ...

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid ...

Under the terms of the latest agreement, CDR-Life could receive up to up to $570m in total payments. This includes ...

Platelet functionality analysis could pave the way to improving drug asset selection and de-risking clinical trials ...

2. Use shared criteria to guide portfolio choices A transparent, data-driven, decision-making framework helps global and ...

The drug candidate has been given breakthrough and priority medicines designations from the FDA and EMA respectively ...

Branded or unbranded? In clinical marketing, this choice shapes how your message lands. Learn how to pick the right strategy ...

But there is also an important R we need, to help maintain our well-being through these turbulent times, and that’s ...

To open up more clinical paths for patients, HCPs need simpler search tools, better access to information and integrated ...

UCB, a global biopharmaceutical company, has announced the final results from its open-label extension (OLE) study evaluating ...

Even with those alarming numbers, the US FDA approvals of disease-modifying therapies (DMTs) such as Leqembi (lecanemab) and ...